Evidence map›Paper›PMID 27593928›Full record

ReviewOncogene2017

Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.

C T Tsai, C W E So

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Gene Transcription as a Therapeutic Target in Leukemia.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. KDM4C contributes to cytarabine resistance in acute myeloid leukemiaTherapeutic advances in chronic disease · 2021
    Article
  15. Review
  16. Article
  17. Histone methyltransferase and drug resistance in cancers.Journal of experimental & clinical cancer research : CR · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

C T TsaiLeukaemia and Stem Cell Biology Group, Division of Cancer Studies, Department of Haematological Medicine, King's College London, Denmark Hill Campus, Rayne Institute, London, UK.
C W E SoLeukaemia and Stem Cell Biology Group, Division of Cancer Studies, Department of Haematological Medicine, King's College London, Denmark Hill Campus, Rayne Institute, London, UK.
King's College London · GB

Funding

Cancer Research UK 16753Medical Research Council G0800892
6 · The paper itself

Abstract

While the current epigenetic drug development is still largely restricted to target DNA methylome, emerging evidence indicates that histone methylome is indeed another major epigenetic determinant for gene expression and frequently deregulated in acute myeloid leukaemia (AML). The recent advances in dissecting the molecular regulation and targeting histone methylome in AML together with the success in developing lead compounds specific to key histone methylation-modifying enzymes have revealed new opportunities for effective leukaemia treatment. In this article, we will review the emerging functions of histone methyltransferases and histone demethylases in AML, especially MLL-rearranged leukaemia. We will also examine recent preclinical and clinical studies that show significant promises of targeting these histone methylation-modifying enzymes for AML treatment.

Indexed as

AcetylationAnimalsAntineoplastic AgentsClinical Studies as TopicDNA MethylationDrug Evaluation, PreclinicalEpigenesis, GeneticHistone DemethylasesHistone-Lysine N-MethyltransferaseHistone MethyltransferasesHistonesHumansLeukemia, Myeloid, AcuteMolecular Targeted TherapyProtein BindingSignal TransductionAntineoplastic AgentsHistone DemethylasesHistone-Lysine N-MethyltransferaseHistone MethyltransferasesHistones

Identifiers

PMID27593928
PMCPMC5378929
OpenAlexW2509664575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.